ScreenIT
The Automated Screening Working Groups is a group of software engineers and biologists passionate about improving scientific manuscripts on a large scale. Our members have created tools that check for common problems in scientific manuscripts, including information needed to improve transparency and reproducibility. We have combined our tools into a single pipeline, called ScreenIT. We're currently using our tools to screen COVID preprints.
Latest preprint reviews
-
Transcriptomic profiling of cardiac tissues from SARS‐CoV ‐2 patients identifies DNA damage
This article has 28 authors:Reviewed by ScreenIT
-
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
This article has 21 authors:Reviewed by ScreenIT
-
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
This article has 34 authors:Reviewed by ScreenIT
-
No magic bullet: Limiting in-school transmission in the face of variable SARS-CoV-2 viral loads
This article has 14 authors:Reviewed by ScreenIT
-
Identification of C270 as a novel site for allosteric modulators of SARS-CoV-2 papain-like protease
This article has 8 authors:Reviewed by ScreenIT
-
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19
This article has 13 authors:Reviewed by ScreenIT
-
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
This article has 7 authors:Reviewed by ScreenIT
-
Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2Omicron variant BA.1 infection of human airway epithelial explant cultures
This article has 12 authors:Reviewed by ScreenIT
-
Contributions of the N-terminal intrinsically disordered region of the SARS-CoV-2 nucleocapsid protein to RNA-induced phase separation
This article has 5 authors:Reviewed by ScreenIT
-
Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial
This article has 73 authors:Reviewed by ScreenIT